Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Blackberry Software is a security Leader.
https://us.blackberry.com/enterprise-of-things
BB
A look at the past year
In 2018, BlackBerry moved from being a smartphone maker to a software licensor of the BlackBerry brand and security software. Given Apple and Samsung’s dominance in the space, this was a good move to retain primary cash flow from a languishing business. License revenue was up, partially offset by a decline in System Access Fees (SAF). However, the main impact of SAF decline is behind the company. In the enterprise mobile management market, it focused on completing product integrating of its Good Technology acquisition and other value-added services such as secure voice and secure document management services. While all right moves, the company also needed to add revenue streams.
John Chen, chief executive officer of BlackBerry Ltd., speaks during the 2018 North American International Auto Show (NAIAS) in Detroit. Photo: © 2018 Bloomberg Finance LP© 2018 BLOOMBERG FINANCE LP
The technology marketplace changed tremendously in 2018 with massive acquisitions, security breaches, harassment scandals and the rapid introduction of AI within many technology products. Given such rapid change, it’s worth taking stock of how different companies fared during this transition and what's next. Lopez Research met with BlackBerry at the Consumer Electronics Show (CES) to discuss the company’s progress and its vision for 2019.
Of course, the talk of CES was automotive and TVs. BlackBerry's QNX real-time operating system enables automakers to build secure and scalable software solutions for connected and autonomous cars. Audi, BMW, Jaguar Land Rover and Toyota use the software for infotainment systems, acoustics and dashboard functions. At CES, the company showcased new infotainment systems built on QNX running in the Audi Q8 and Karma Revero. Despite intense competition and noise in the space, QNX is embedded in 125 million vehicles today. However, the road ahead for BlackBerry in 2019 requires successfully executing in strategies that support embedded operating systems, Internet of Things platforms and security solutions.
BlackBerry extended its portfolio deeper into the Enterprise of Things, defined as the Internet of Things (IoT) for in the enterprise. The challenge for any vendor in the IoT space is to design products that can be customized to deliver multiple solutions to support various industries. To drive adoption, BlackBerry focused on providing vertical industry solutions in areas such as automotive, healthcare, government and logistics. For example, BlackBerry Radar is an IoT solution focused on asset tracking and health for the transportation and logistics industry.
Its BlackBerry Spark Enterprise of Things (EoT) platform offers ultra-secure connectivity from the kernel to the edge for applications in the automotive and industrial space. BlackBerry Spark offers secure chip-to-edge communications platform for EoT to create trusted connections between any endpoint. Another example of BlackBerry’s security and EoT focus is the Jarvis static application testing platform that can help automakers and other embedded developers to secure their software supply chains.
Surprisingly, BlackBerry also added more consulting services to its arsenal in a bid to become the security software and service provider of choice for healthcare and automotive services. For example, it announced it had become a HIMSS Analytics Certified Consultant to guide healthcare organizations through the stages of the Infrastructure Adoption Model (INFRAM), as well as ERAM.
IoT: A hard market for everyone
Unfortunately for BlackBerry and other technology vendors, the IoT marketplace evolved slower than Lopez Research and others predicted. Most enterprises were at a loss for how to execute on a connected company strategy. Results from Cisco Systems research came to a similar conclusion. Cisco’s survey revealed that 60 percent of IoT initiatives stall at the Proof of Concept (PoC) stage and only 26 percent of companies have had an IoT initiative that they considered a complete success.
IoT isn’t like networking or mobility where you can deliver a set of technologies in isolation. IoT strategies work best when the plan combines hardware, software and communications from multiple vendors. These solutions take time and integration amongst various technology vendors. This need for designing and integrating solutions has set back technology adoption and delayed the turnaround of companies like BlackBerry. On the positive side, BlackBerry’s solutions have an industry focus and during the year the company announced both academic and industry partnerships to support IoT efforts.
Security: The final frontier
To broaden its footprint in the security market, it acquired CA-based cybersecurity firm Cylance for $1.4 billion in cash. In June of 2018, Cylance reported that it had annual revenues of over $130 million for the fiscal year 2018, over 90% year-over-year growth, and more than 4,000 customers. Over 20% of the Fortune 500 use its solutions. Cylance uses AI methods such as algorithmic science and machine learning to protect mobile devices, tablets and other Internet-connected devices from cyber attacks. The software is designed to consume less power, both in online and offline modes. While it’s too early to tell what impact that will have on the company’s revenue, the acquisition is a good indicator of how BlackBerry plans to deepen its foothold in the security marketplace.
Specifically FDA or CFIA approval needed. Lots of companies partner with government agencies to further their projects doesn't mean they are getting CFIA Canada approval or FDA approval for USA.
Thanks for your opinion.
Horizon Bull do you know if IMLFF has to go through any government approval before they are able to use their Bio synthesis platform to sell synthetic cannabinoids the public or other companies? thanks in advance!
Which of These Two Tech Companies Is the Better IoT Stock?
Jason Phillips | February 24, 2019 | More on: SWIR BB
https://www.fool.ca/2019/02/24/which-of-these-two-tech-companies-is-the-better-iot-stock/
Technology experts are widely anticipating that the Internet of Things (IoT) is on the verge of morphing into a revolutionary application that stands to affect our lives in countless ways.
Research firm Gartner estimates that around 8.4 billion IoT devices were already connected to the world wide web as of 2017, with that figure expected to grow to as many as 20.4 billion devices by 2020 with total spending on all things IoT forecasted to reach as much as $2 Trillion globally by that time, if not sooner.
Companies from all walks of life are anxious to connect their products and services to the internet in the pursuit of not only providing a richer user experience for their customers, but also in the pursuit of harnessing the power of “big data” in order to allow them greater insight into consumer behaviour (and spending) patterns.
Naturally, such a revolutionary technology will have far reaching effects across industry.
Not only do telecommunications companies stand to benefit from adding more devices to their networks that consume ever greater quantities of data, but a couple of Canadian information technology companies are focusing their efforts on harnessing the potential of IoT technology.
Enter BlackBerry Ltd (TSX:BB)(NYSE:BB) and Sierra Wireless, Inc. (TSX:SW)(NASDAQ:SWIR).
Most readers will be familiar with BlackBerry from its rise to glory as one of the first tech companies to revolutionize smart-phone technology.
But in case you haven’t been keeping up with the Waterloo-based firm, the company is no longer involved in selling smart-phone headsets, having exited its declining hardware business some time ago.
Instead, CEO John Chen has taken over the reins and is redesigning the company as an industry leader in software and cybersecurity.
Playing to the strengths that it once enjoyed when it sat atop the throne of smart-phone manufacturers, Chen hopes to take advantage of the opportunity he sees in the cybersecurity aspect of the IoT.
As Chen sees it, each additional device that gets added to the internet represents an additional point of vulnerability for businesses and organizations.
As such, Chen hopes that his firms leading-edge security solutions, which have already garnered high praise by industry to date and will be able to capture a sizeable share of the IoT market.
Sierra Wireless meanwhile is a much smaller enterprise, with a market capitalization of just $603 million versus BlackBerry’s $ 6.11 billion value.
Like BlackBerry, Sierra is focused on the potential of the global IoT market – a focus that includes a product suite of management solutions that allow organizations to better enable them to keep mission critical workers and assets connected to the enterprise.
However the truth is that Sierra is coming off a disappointing Q4 report that included the company’s first earnings miss in two years.
On the bright side, the revenues at the firm continue to grow close to double-digits, including some particularly strong showings in the firm’s services business, which it hopes it can add to going forward thanks to an organizational restructuring that will see the firm centralize both its R&D and sales functions.
Conclusion
If and when the IoT boom takes hold, which may be aided by the forthcoming rollout of 5G wireless networks globally, both BlackBerry and Sierra Wireless should expect a lift in their respective share prices.
As far as which one is the better play for right now, I’d tend to go with BlackBerry primarily because of the two it appears to be further ahead in its reorganization into a software and services focused company.
Not to mention that the roughly $2 billion or so in cash and short-term investments that BlackBerry currently has on its books doesn’t hurt the case for it being the safer investment of the two on a relative basis, either.
Conversely, I could see Sierra having further room to run down before the share price turns around, if only because the firm is coming off such a long streak of earnings beats and it may take some time before the latest momentum swing runs its course.
Meanwhile, the smaller stature of Sierra’s operational footprint one could argue gives it a considerably longer runway longer term.
BlackBerry QNX - The software Platform for the car-smart cities-IOTA-Autonomous Cars. (Video)
Blackberry accuses Twitter of illegally using message technology in lawsuit
https://mashable.com/article/blackberry-sues-twitter-patents/#rIJpo4ahaZqP
Global IoT Market 2018-2025 Top Players – Amazon Web Services, Autodesk SeeControl, BlackBerry
http://industrynewsnetwork.com/2019/02/05/global-iot-market-2018-2025-top-players-amazon-web-services-autodesk-seecontrol-blackberry/
MRS Research Group recently Published Global IoT Market research study with more than 100 industry informative desk and Figures spread through Pages and easy to understand detailed TOC on “IoT Market”.
Global IoT market 2019 research helps you to achieve positive growth and allow different methods for maximizing your profit. The market study provides estimates for Global IoT Market 2019 analysis and Forecast till 2025. Some of the Leading key Company’s Covered for this Research are Amazon Web Services , Autodesk SeeControl , BlackBerry , Bosch Software Innovations , Bright Wolf , C3 IoT , Carriots , Concirrus , Connio , Cumulocity , Davra Networks , Device Insight , EVRYTHNG , Exosite , General Electric , ,
Global IoT market engineering comprises the structured, systematic and theoretically founded procedure of analyzing, designing, introducing and also quality assuring of markets as well as their legal framework regarding simultaneously their market mechanisms and trading rules, systems, platforms and media, and their business models.
The IoT market can be Devided based on product types and It’s sub-type, major applications and Third Party usage area, and important regions.
Global IoT Research for a Leading company is an intelligent process of gathering and analyzing the numerical data related to services and products. This Research Give idea to aims at your targeted customer’s understanding, needs and wants. Also, reveals how effectively a company can meet their requirements.
Click Here to Get Free Sample PDF Copy of Latest Research on IoT Market 2019 : www.mrsresearchgroup.com/report/137742#request-sample
market research is any organized effort to gather information about targeted market which is IoT . It is a very important component of business strategy. The term is commonly interchanged with marketing research; however, expert Market research is one of the main factors used in maintaining competitiveness over competitors.
Why Global IoT market 2019 Research Report ?
1.Market research provides important information which helps to –
Identify and analyze the needs of the market,
The market size and the competition.
2. Market-research techniques encompass both qualitative techniques such as –
Focus groups,
In-depth interviews,
Ethnography,
https://www.forbes.com/sites/greatspeculations/2018/01/05/why-blackberrys-autonomous-driving-deal-with-baidu-is-significant/#7ef62f6940a1
Why BlackBerry's Autonomous Driving Deal With Baidu Is Significant
BlackBerry signed a deal with Chinese internet giant Baidu to jointly develop self-driving vehicle technology, in what is seen as a shot in the arm for BlackBerry’s automotive ambitions. BlackBerry’s stock rose by about 13% in Wednesday’s trading following the announcement. While BlackBerry has been partnering with several companies that intend to use QNX for their autonomous driving systems, the Baidu deal is notable as it could give the company greater traction in China, the world’s largest automotive market.
We have a $9 price estimate for BlackBerry which is below the current market price.
Baidu’s Approach To Autonomous Cars Is Focused On Scale
Baidu, which is primarily known for its search engine, it is also a leader in the development of deep learning and artificial intelligence. The company is leveraging these strengths to create an open-source autonomous driving platform called Apollo, which it hopes will ensure more rapid development and higher proliferation of autonomous cars. With the BlackBerry deal, Baidu intends to use the QNX operating system as the foundation for its Apollo platform. The platform has been described as the Android of the automotive industry, as it is both modular as well as open source, allowing developers to pick and choose the features they want to use in their systems. Apollo has signed agreements with several large auto companies, including Ford, Hyundai and some Chinese automotive manufacturers. The platform has also attracted partnerships from Tier 1 suppliers, developer platforms, and technology startups. The two companies will also work together to integrate Baidu’s CarLife automotive system with its conversational AI system DuerOS, and high definition maps to run BlackBerry’s infotainment platform.
BlackBerry’s Automotive Ambitions
Software is playing an increasing role in automobiles, with software and electronics estimated to account for upwards of 30% of a modern automobile’s cost. The role of software in automobiles is likely to rise with the advent of autonomous driving systems, and BlackBerry has been looking for early market share gains by forging deals with the largest automotive industry chip suppliers, as well as partnerships with the top three tier-1 auto suppliers – Bosch, DENSO, and Magna. That said, competition is likely to remain strong in this nascent market, with companies ranging from silicon valley giants such as Apple and Google to automotive suppliers doubling down on the market. BlackBerry does bring a lot of strengths to the space given its expertise in security and communications technologies. Moreover, the company’s QNX software has been known to operate mission-critical applications such as medical devices, air traffic control, and control systems. This could give the company some competitive advantages over the long run.
https://www.bitrates.com/news/p/blackberrys-rebirth-using-blockchain-to-help-store-and-share-medical-research
BlackBerry Ventures Into Autonomous Car Security | PYMNTS.com
https://www.pymnts.com/innovation/2018/how-cars-came-to-drive-blackberrys-future/
https://www.theregister.co.uk/2017/09/21/delphi_automotive_picks_blackberry_qnx_for_autonomous_cars/
https://www.forbes.com/sites/greatspeculations/2018/01/05/why-blackberrys-autonomous-driving-deal-with-baidu-is-significant/#7ef62f6940a1
BlackBerry Leverages Blockchain to Disrupt Legacy Healthcare
Following the announcement of BlackBerry Spark, an Enterprise of Things platform for ultra-secure hyperconnectivity, BlackBerry Limited announced new partnerships and projects with the shared goal of transforming the global delivery of healthcare and patient care.
BlackBerry, a smartphone line created by BlackBerry Limited, is well-known for the keyboards on most of its devices and mobile productivity.
According to John Chen, Executive Chairman, and CEO of BlackBerry Limited:
“We are applying our expertise in security, data privacy, and communication work in regulated industries such as automotive, financial services, and government to tackle one of the biggest challenges in the healthcare industry: leveraging healthcare endpoints to improve patient outcomes while ensuring security and data privacy.”
BlackBerry Limited will use its carrier-grade network operation center (NOC) to fuel a distributed ledger, offered by ONEBIO, to create an ultra-secure global connection for storing and distributing medical data. An example of this innovation is such that data could be entered by laboratories, patients, medical institutions and devices containing biometric measurements and made anonymous to be shared and used by researchers.
Who will adopt BlackBerry’s platform?
BlackBerry is offering the new healthcare product first to the Global Commission, an organization dedicated to ending the diagnostic odyssey for children with rare diseases.
Co-chaired by Shire, the primary global biotechnology company focused on rare diseases, a pilot of the Global Commission will investigate how BlackBerry’s new solution could provide live and thorough analysis as the organization aims to shorten the time to diagnose uncommon diseases.
Who are BlackBerry’s partners?
BlackBerry has partnered with the Mackenzie Innovation Institute, an organization that works with academic partners to identify new technologies or processes that can more effectively solve issues in the healthcare ecosystem.
According to Richard Tam, Chief Financial Officer of the Mackenzie Innovation Institute:
“By developing a deeper understanding and exploring how our ‘smart’ systems operate with BlackBerry Spark, we aim to uncover new ways to connect, protect and intuitively manage smart technologies in a hospital and positively impact high-quality patient care.”
https://cryptoslate.com/blackberry-leverages-blockchain-to-disrupt-legacy-healthcare/
BlackBerry Leverages Blockchain to Disrupt Legacy Healthcare
Following the announcement of BlackBerry Spark, an Enterprise of Things platform for ultra-secure hyperconnectivity, BlackBerry Limited announced new partnerships and projects with the shared goal of transforming the global delivery of healthcare and patient care.
BlackBerry, a smartphone line created by BlackBerry Limited, is well-known for the keyboards on most of its devices and mobile productivity.
According to John Chen, Executive Chairman, and CEO of BlackBerry Limited:
“We are applying our expertise in security, data privacy, and communication work in regulated industries such as automotive, financial services, and government to tackle one of the biggest challenges in the healthcare industry: leveraging healthcare endpoints to improve patient outcomes while ensuring security and data privacy.”
BlackBerry Limited will use its carrier-grade network operation center (NOC) to fuel a distributed ledger, offered by ONEBIO, to create an ultra-secure global connection for storing and distributing medical data. An example of this innovation is such that data could be entered by laboratories, patients, medical institutions and devices containing biometric measurements and made anonymous to be shared and used by researchers.
Who will adopt BlackBerry’s platform?
BlackBerry is offering the new healthcare product first to the Global Commission, an organization dedicated to ending the diagnostic odyssey for children with rare diseases.
Co-chaired by Shire, the primary global biotechnology company focused on rare diseases, a pilot of the Global Commission will investigate how BlackBerry’s new solution could provide live and thorough analysis as the organization aims to shorten the time to diagnose uncommon diseases.
Who are BlackBerry’s partners?
BlackBerry has partnered with the Mackenzie Innovation Institute, an organization that works with academic partners to identify new technologies or processes that can more effectively solve issues in the healthcare ecosystem.
According to Richard Tam, Chief Financial Officer of the Mackenzie Innovation Institute:
“By developing a deeper understanding and exploring how our ‘smart’ systems operate with BlackBerry Spark, we aim to uncover new ways to connect, protect and intuitively manage smart technologies in a hospital and positively impact high-quality patient care.”
--------------------------------------------------------------------------------------------------------
BlackBerry wants to be the software behind smart cities & Autonomous Cars.
https://www.techradar.com/news/blackberry-wants-to-be-the-software-behind-smart-cities
--------------------------------------------------------------------------------------------------------
Blackberry, Feds Spending $350 Million On Future Car Tech.
https://www.autotrader.ca/newsfeatures/20190216/blackberry-feds-spending-350-million-on-future-car-tech/
-------------------------------------------------------------------------------------------------------
BlackBerry is buying an AI security firm for $1.4 billion — here's how it could help the company capitalize on demand for IoT security.
https://www.businessinsider.com/blackberry-acquires-cylance-ai-security-2018-11
Blackberry Blockchain and internet of things Blue Chip
BlackBerry Healthcare Momentum Continues with Latest HIMSS INFRAM Certification
Healthcare: Encryption Of Things (EOT)
http://blogs.blackberry.com/2018/11/blackberry-healthcare-momentum-continues-with-latest-himss-infram-certification/
Last month, BlackBerry announced several major healthcare developments, including the introduction of a secure blockchain solution to store and share medical data, an ultra-secure operating system for medical devices, and partnerships with Mackenzie Innovation Institute and Melanoma Institute Australia.
Bolstering this momentum, BlackBerry today announced it is a HIMSS Analytics Certified Consultant, which will enable the company to help address the digital infrastructure needs of healthcare organizations around the world. As a Certified Consultant, BlackBerry’s cybersecurity experts have been professionally trained to guide healthcare organizations through the stages of the Infrastructure Adoption Model (INFRAM), HIMSS Analytics’ newest Maturity Model, as well as the existing and prevalent Electronic Medical Record Adoption Model (EMRAM).
We sat down with BlackBerry’s Global Healthcare Industry Lead Sara Jost and Global Head of Cybersecurity Services Campbell Murray to learn more about their work with HIMSS Analytics and overall work in healthcare.
Q: Why did BlackBerry want to become a HIMSS certified consultant? What do you feel BlackBerry brings to the table?
Sara: As healthcare shifts to be increasingly digital – whether that be in connected hospitals, wearable devices and implants, or more advanced research projects – HIMSS recognized that strong cybersecurity expertise and communication and collaboration tools are required to address the current healthcare landscape. This is what BlackBerry brings.
Campbell: I believe our heritage and deep expertise in building ultra-secure devices, combined with the more than 50 independent credentials, proves that customers won’t have to take our word for it when we say that our teams are the elite standard of security services.
Q: BlackBerry has a longstanding reputation for security, but HIMSS INFRAM is also about infrastructure. What is the intersection point that BlackBerry is going after?
Sara: BlackBerry’s cybersecurity experts will assess vulnerabilities in a hospital’s infrastructure, devices, and configurations, using a wide range of penetration testing, social engineering techniques, and physical security assessments. We will also work with them to identify solutions to fix and/or strengthen their infrastructure.
Q: How will HIMSS INFRAM make a difference to healthcare organizations?
The HIMSS INFRAM framework is an eight-stage model (0 – 7) that allows healthcare IT leaders to map the technology infrastructure capabilities required to reach their facility’s clinical and operational goals while meeting industry benchmarks and standards.
By following the INFRAM process, healthcare organizations make the most of their infrastructure by identifying areas, such as technical debt and overspend, to drive efficiency in the transport and security of electronic medical records – ultimately to improve patient outcomes.
Q: Why do hospitals need to care about cybersecurity?
Campbell: Healthcare is an industry under siege. As the IoT/EoT expands, so does the attack surface for hackers who are getting more and more sophisticated. Every connected thing in a hospital – including those of suppliers and distributors – is a potential target that needs specialized protection from today’s growing cybersecurity threats.
Security is no longer just about protecting our data. It’s about protecting our health, our safety and our well-being, which is why our cybersecurity team is excited to work with more healthcare providers to improve their security posture, procurement standards, and ensure vendor claims can be verified. We’ll also work with them to develop a robust plan to deal with any future cyberattacks and get them back up and running as soon as possible.
Q: What can we expect from BlackBerry as it relates to healthcare in the coming year?
Sara and Campbell: More exciting partnerships and news related to our work in healthcare! In today’s hyperconnected world, hospitals need ultra-security, which is exactly what we provide.
BlackBerry Spark:
The EoT Platform for Ultra-secure Hyperconnectivity
https://www.blackberry.com/us/en/products/blackberry-spark-platform
http://blogs.blackberry.com/
Cylance | Artificial Intelligence Based Advanced Threat Prevention:
https://www.cylance.com/en-us/index.html
-------------------------------------------------------------------------------------------------------
Cylance is revolutionizing cybersecurity with AI based solutions that predict and prevent execution of advanced threats and malware at the endpoint.
https://www.forbes.com/sites/greatspeculations/2018/11/26/why-blackberrys-acquisition-of-cylance-makes-sense/#511b7897a664
------------------------------------------------------------------------------------------------------
https://www.apnews.com/95be058eab4141f28f41d0c368eb682b
CylancePROTECT Now Available on AWS Marketplace
------------------------------------------------------------------------------------------------------
BlackBerry Cylance Wins Cybersecurity Excellence Awards in Five Categories:
https://www.prnewswire.com/news-releases/blackberry-cylance-wins-cybersecurity-excellence-awards-in-five-categories-300803958.html
----------------------------------------------------------------------------------------------------
Ottawa is giving BlackBerry $40 million to help develop self-driving cars
https://business.financialpost.com/technology/blackberry-to-get-40m-in-federal-funds-to-support-self-driving-car-development
----------------------------------------------------------------------------------------------------
Blackberry, Feds Spending $350 Million On Future Car Tech
https://www.autotrader.ca/newsfeatures/20190216/blackberry-feds-spending-350-million-on-future-car-tech/
BB Blackberry.
Blackberry -QNX operating systems, development tools, and professional services ...
www.qnx.com/
Internet of things: autonomous cars.
BlackBerry QNX empowers leading OEMs to build secure, scalable, and trusted software solutions that enables the future of connected and autonomous cars.
The Engine behind the Connected Car
In today’s market, Automakers are challenged by regulatory and consumer demands.
To improve fuel efficiency while adding more electronic systems and reducing noise, vibration and harshness (NVH).
To improve safety while introducing advanced connectivity and infotainment features.
To improve security while enabling more accessibility.
To reducing development costs while bringing new features to market.
To use common platforms but enable brand differentiation.
Only BlackBerry QNX offers a broad portfolio of software solutions for the future of the automotive industry - cluster, Infotainment, connectivity, in-car network security, type-1 hypervisor supporting multiple ECU integration into domain controllers, ADAS, and acoustics. Our Over-The-Air (OTA) software update platform, ensures secure software lifecycle management of automotive software for the life of the platform. As the choice of leading OEM’s today, BlackBerry QNX, provides flexible, scalable solutions that enable today’s vehicle systems and next generation of connected and autonomous vehicle architectures.
http://blackberry.qnx.com/en/solutions/industries/medical/index
Trusted OS platform and technology partner for safety-critical medical devices
As medical devices become more connected, addressing the issues of runaway healthcare costs and healthcare access, robust, reliable and secure performance in medical device design are defining differentiators. For over 30 years, QNX® has been providing a full-featured, multi-core development platform that exceeds the most demanding requirements for reliability, performance, data safety, and security. With QNX's IEC 62304 conforming OS, field-proven portfolio of pre-integrated technologies, solutions, and a broad partner ecosystem, developers can focus on their IP in application design and functionality, leaving the platform heavy lifting to us.
http://blackberry.qnx.com/en/solutions/industries/automation/index
Manufacturers today face the challenge of producing increasingly complex systems that maximize production uptime, minimize risks, and reduce costs. In fact, today’s software must be reusable across multiple product lines and enable manufacturers to create complex connected systems that run non-stop and remain in-field for a very long time.
http://blackberry.qnx.com/en/solutions/industries/defense/index
Military-grade security and reliability in mission-critical government and military systems where information is vital and lives can be at stake, downtime is not an option.
The need for a highly reliable, secure, and fast operating system is crucial. It is these systems that require the highest level of confidence and fault tolerance that comes from a proven technology, battle-hardened in over 30 years of field deployment.
Thanks to the true microkernel architecture of the QNX Neutrino® RTOS, full memory protection is built in. Any component can fail and be dynamically restarted without corrupting the microkernel or other components. If a failure does occur, a QNX-based system has the capability for self-healing through critical process monitoring and customizable recovery mechanisms.
http://blackberry.qnx.com/en/solutions/industries/rail-safety/index
Functional safety is a key requirement in industries where real-time performance goals and mission-critical reliability is imperative.
Achieving certification to functional safety standards brings a new dimension of challenges. To address these challenges the QNX® OS for Safety is designed specifically for industrial, railway transportation and robotic systems that are required to be compliant with functional safety standards, such as IEC 61508 and market-specific standards derived from it. The product has been pre-certified by a leading auditing firm, TÜV Rheinland, as a compliant item for use in systems up to IEC 61508:2010 SIL3.
QNX Medical Overview
Explore the Solution
The knowledge level for functional safety and certification is one of the most important deciding factors for project success. Generally speaking, a project with functional safety certification requirements can easily double or triple the time it takes to complete a project without. Efforts invested in certification activities are often greater than efforts in straight development. This magnifying effect of the certification requirements is abated when knowledge level is high and amplified when knowledge level is low. The table below shows a fictitious scenario to illustrate this effect, assuming a development team with fairly a good knowledge in safety and certification.
Using pre-certified components lower overall risk to system manufacturers through proven and reliable technologies. One of the most vital components in complex platforms consisting of hardware and software is the real-time operating system. A pre-certified operating system (OS) offers a high level of reliability and risk reduction for safety-critical systems that has been independently validated. It would be difficult to imagine a certified industrial control application without a pre-certified OS. This is an additional dimension to the build-or-buy decision for system manufacturers. Some companies have legacy home-grown components including operating systems. In most cases, the cost of certifying these home-grown components will outweigh the price tag of a pre-certified solution, simply due to the economy of scale factor. Hardware is a different story. Pre-certified hardware is difficult to find and hardware certification is a frequently asked question from system manufacturers.
Ecosystem partners
The Modular Train Control System (MTCS) from MEN Mikro Elektronik offers a pre-integrated, ready to install platform that combines the ideal operating system from QNX Software Systems for reliability and easier programming of safety critical applications with the F75P solution, representing an extremely compelling offer to address regulatory pressures and cost effectiveness challenges. In addition to pre-certification credentials, MTCS offers high level of flexibility for system integrators, resulting in significant cost and time savings during computerization of the train. The combined solution allows users to quickly create new solutions which take advantage of the latest industrial safety and processing speed and real-time automation technology while allowing them to reuse or adapt existing automation algorithms.
------------------------------------------------------------------------------------------------------
Massive Upside Machine Learning Cybersecurity-Internet of Things Blackberry transitioning to AI & IOTA software company.
Inmed IMLFF sued by Calgary man over 2016 private placement
2019-02-25 10:33 ET - Street Wire
by Mike Caswell
Inmed Pharmaceuticals Inc. is a defendant in a lawsuit filed in the Supreme Court of British Columbia by Calgary businessman Hussein Charanek over a private placement that went awry. Mr. Charanek claims that he was supposed to receive shares in an eight-cent financing that the company arranged in 2016. The stock was supposed to come to him in a roundabout way, through one of the company's employees, but he never received the shares, the suit claims.
The allegations are contained in a notice of claim that Mr. Charanek filed at the Vancouver courthouse on Thursday, Feb. 21. The suit names as defendants Inmed and the company's senior vice-president of investor relations, Christopher Bogart. Mr. Charanek's complaint centres around a $1.5-million financing that the company disclosed on Oct. 6, 2016, comprising 18.75 million units at eight cents.
Mr. Charanek claims that he was supposed to be one of the subscribers to that placement, contributing $400,000. He says that he met with Mr. Bogart and others at the company's office on Oct. 21, 2016, to allocate the amounts among the individual investors. The problem, as set out in the lawsuit, arose when the company decided that it would close the financing five days later. Mr. Charanek was not able to immediately deliver the $400,000 to the company's office.
The value of biosynthesis.
The Baseline is $10-$100 per Gram of CBD depending on the size of your order and purity. Once you get away from the over the counter extracts and into the pharmaceutical grade the prices start to go up considerably. For >98% pure pharmaceutical grade research CBD in crystalline form, the price goes to $5-$10 per milligram.
CBD is or will become a commodity and we are more interested in the minor cannabinoids so I wanted to know what the market is. If there is a price to be found, there is a market to sell them. So I did a scan of a few chemical companies (Cayman Chemical, Sigma Aldrich and Toronto Research Chemicals) that provide research grade cannabinoid compounds and got some prices. I've listed about 55 Cannabinoids and put in prices where they could be found. Feel free to add in more if you can find them.
#8 is CBD and it's calculated in grams where everything else is in milligrams. Just for your reference Cayman Chemical sells 98% pure crystalline pharmaceutical-grade CBD for about $5 per milligram.
Long to short, there is some serious profit to be had!
Cannabichromenes
1. Cannabichromene (CBC) - $97 per mg
2. Cannabichromenic acid (CBCA) - $249 per mg
3. Cannabichromevarin (CBCV) - $195 per mg
4. Cannabichromevarinic acid (CBCVA) - $4000 per 100mg
Cannabicyclols
5. Cannabicyclol (CBL) $95 per mg
6. Cannabicyclolic acid (CBLA) $151 per 0.5mg in 1 ML - $302 per mg
7. Cannabicyclovarin (CBLV) price not public - via RFQ only
Cannabidiols
8. Cannabidiol (CBD) 98% pure - $5 per mg
9. Cannabidiol monomethylether (CBDM)
10. Cannabidiolic acid (CBDA) - $159 per mg
11. Cannabidiorcol (CBD-C1) - $20 per mg - $700 per 50 mg.
12. Cannabidivarin (CBDV) - $65 per 1mg to $149 per mg certified
13. Cannabidivarinic acid (CBDVA) - $275 per 1 ML / 1mg
Cannabielsoins
14. Cannabielsoic acid B (CBEA-B)
15. Cannabielsoin (CBE) - $100 per 1mg
16. Cannabielsoin acid A (CBEA-A)
Cannabigerols
17. Cannabigerol (CBG) - $95 per mg
18. Cannabigerol monomethylether (CBGM)
19. Cannabigerolic acid (CBGA) - $125 - 165 per mg
20. Cannabigerolic acid monomethylether (CBGAM)
21. Cannabigerovarin (CBGV) - $89 per mg
22. Cannabigerovarinic acid (CBGVA) - $128 per mp
Cannabinols and cannabinodiols
23. Cannabinodiol (CBND) - $65 per mg
24. Cannabinodiol (CBVD)
25. Cannabinol (CBN)- $32 - 65 per mg
26. Cannabinol methylether (CBNM) - $65 per mg
27. Cannabinol-C2 (CBN-C2)
28. Cannabinol-C4 (CBN-C4)
29. Cannabinolic acid (CBNA) $263 per 1 ML / 1mg
30. Cannabiorcool (CBN-C1)
31. Cannabivarin (CBV) $95 per 1mg
Cannabitriols - pricing unknown
32. 10-Ethoxy-9-hydroxy-delta-6a-tetrahydrocannabinol
33. 8,9-Dihydroxy-delta-6a-tetrahydrocannabinol
34. Cannabitriol (CBT)
35. Cannabitriolvarin (CBTV)
Delta-8-tetrahydrocannabinols
36. Delta-8-tetrahydrocannabinol (?8-THC) - $32-60 per mg
37. Delta-8-tetrahydrocannabinolic acid (?8-THCA)
Delta-9-tetrahydrocannabinols
38. Delta-9-tetrahydrocannabinol (THC) -
39. Delta-9-tetrahydrocannabinol-C4 (THC-C4)
40. Delta-9-tetrahydrocannabinolic acid A (THCA-A) - $149 per mg
41. Delta-9-tetrahydrocannabinolic acid B (THCA-B)
42. Delta-9-tetrahydrocannabinolic acid-C4 (THCA-C4)
43. Delta-9-tetrahydrocannabiorcol (THC-C1)
44. Delta-9-tetrahydrocannabiorcolic acid (THCA-C1)
45. Delta-9-tetrahydrocannabivarin (THCV) - $179 per mg
46. Delta-9-tetrahydrocannabivarinic acid (THCVA)
Miscellaneous cannabinoids
47. 10-Oxo-delta-6a-tetrahydrocannabinol (OTHC)
48. Cannabichromanon (CBCF)
49. Cannabifuran (CBF)
50. Cannabiglendol
51. Cannabiripsol (CBR)
52. Cannbicitran (CBT) - $100 per mg.
53. Dehydrocannabifuran (DCBF)
54. Delta-9-cis-tetrahydrocannabinol (cis-THC)
55. Tryhydroxy-delta-9-tetrahydrocannabinol (triOH-THC)
https://www.cantechletter.com/2019/02/the-future-of-cannabis-is-in-the-lab-says-altacorp-capital/
https://insiderfinancial.com/inmed-pharmaceuticals-inc-otcmktsimlff-comeback-trail
Bottom Line we are literally a few quarters from disrupting the whole industry with Inmed Pharma bio synthesis platform. This has massive upside potential 100-200x ROI
James Hodgins, chief investment officer at Curvature Hedge Strategies, discusses InMed Pharmaceuticals. 3 days ago
https://www.bnnbloomberg.ca/investing/video/james-hodgins-discusses-inmed-pharmaceuticals~1394817
IMLFF scaling up Bio Synthesis when this is complete later this year IMLFF will be off to new 52 week highs and depending on partnerships and revenue for Bio Synthesis this could be 10.00+ within a year.
Life changing money.
InMed Pharmaceuticals disrupting cannabinoid space with biosynthesis technology
http://theseedinvestor.com/articles/37-year-old-diabetes-discovery-set-to-launch-tiny-marijuana-biotech-stock
37-Year Old Diabetes Discovery Set To Launch Tiny Marijuana Biotech Stock?
A diabetes diagnosis was once a veritable death sentence. A century ago the average life expectancy for a 30-year old with diabetes was just four years.
Then a discovery in 1921 changed all that.
A team of Canadian researchers discovered a way to process pig pancreases into a human insulin replacement. That single discovery changed diabetes from death sentence to chronic disease.
Now, turning pig pancreases into human insulin was anything but an efficient or inexpensive process. It took about 5,000 pig pancreases to produce just eight ounces of insulin.
You can imagine how much money, time, and pig pancreases it would take to treat thousands of diabetes sufferers for years. The process was expensive, complicated and time-consuming, but it was also wildly lucrative.
Eli Lilly – based in Indianapolis, Indiana – led the way in manufacturing insulin from animal organs.
The company’s centralized location relative to the majority of American pig farms made it the ideal insulin producer.
Eli Lilly had a dominant position for nearly 60 years and made a fortune at it too.
Of course, big money like that — literally tens of billions of dollars — created big opportunity for small, highly innovative companies.
That’s just what happened too. It created an entirely new era in biotech, leading a small company on a growth trajectory from just two co-founders to a $48 billion takeover, and now another tiny company is following on the exact same trajectory.
The Birth of Big Biotech
For nearly 60 years Eli Lilly grew to dominate the insulin replacement market. However, one company made a discovery in the early 1970s that would risk Eli Lilly’s insulin processing cash cow.
In the early 1970s, then tiny and innovative biotech company found that it could combine strains of E. coli bacteria with human genes to produce what’s called a “biosynthetic insulin.”
The process was better in every way. It was simpler, faster, and, since it was done in a lab instead of by industrial-level processing of pig pancreases, it was far cheaper.
It’s safe to say that without this discovery animal-derived insulin would have been an expensive treatment reserved for only the most severe cases. Within a few years the new biosynthetic insulin nearly replaced all animal pancreas-based insulin and the industry hasn’t looked back.
Genentech-lilly-The global diabetes pandemic has turned that single innovation in the early 1970s into a $35 billion a year industry today. That small company discovered biosynthetic insulin was Genentech.
Genentech ended up partnering with Eli Lilly to produce biosynthetic insulin and both companies grew steadily ever since.
Eli Lilly is now a $73 billion pharmaceutical giant.
Genentech was acquired by Swiss pharmaceutical giant Roche Holdings for $48 billion at the bottom of the credit crisis in early 2009 (right before the biotech sector went on to rise 500% in the following stock market rally).
In the end, this single innovation made big money for the giant partner and led the way for a massive fortune for the early founders of the innovative Genentech by solving one simple and expensive problem.
Now one tiny biotech company is targeting the exact same thing as Genentech with the booming cannabis industry.
Big Biotech Meets Marijuana
InMed Pharmaceuticals (IMLFF) is a tiny biotech company with an innovative approach that’s set to play a major role in the marijuana boom.
InMed’s run – much like Genentech in the 1970s — is just getting started too.
Marijuana has a long and complicated history in the world.
The plants’ psychedelic properties make it an illegal narcotic in most of the world. It has many side effects. It used to be believed that Long-term use might significantly and negatively affect cognitive functions.
There were also, undoubtedly, some medicinal properties to marijuana too.
Just look at GW Pharmaceuticals (GWPH) to see what I mean.
GW Pharmaceuticals has successfully isolated a particular part of the marijuana plant, one of nearly a hundred “cannabinoids,” which offers those medicinal properties.
The company has discovered, proven, and brought to market a multiple sclerosis treatment that’s approved for use in dozens of countries.
GW Pharmaceuticals has also isolated another cannabinoid which can be effectively and safely used for the treatment of epilepsy that’s in the final stages of trials before getting approval and hitting the market.
The success of GW in developing pharmaceutical drugs from marijuana over the last few years has sent its shares from less than $9 in 2013 to more than $110 in 2016 and earned it a market value of more than $2.9 billion.
Much like Eli Lilly did in the middle of the last century, when it was shipping in millions of animal pancreases in order to produce a few ounces of animal-derived insulin, GW Pharmaceuticals has a big and fundamental problem.
GW Pharmaceuticals has to buy mountains of marijuana from growers to isolate and extract the key ingredients to produce its drugs.
The costs are enormous.
The marijuana industry has to grow millions of plants at a cost of tens of millions of dollars just to get to enough of those one or two vital cannabinoid ingredients that makes GW Pharmaceuticals drugs effective.
It’s costly.
Too costly.
And one company has advanced the technology to bring the same technology that made insulin treatment available to the masses to bring the medicinal properties of marijuana to millions who suffer from common diseases at an affordable price.
InMed Pharmaceuticals (IMLFF) is a tiny company with a single big idea — use biosynthesis to create the cannabinoids found in tiny amounts in naturally grown marijuana.
InMed has developed and patented a technologically advanced process to isolate and the active cannabinoids (those are the parts of the marijuana plant with proven medicinal properties) and produce them biosynthetically.
It’s just like what Genentech discovered in the 1970s when it took a natural and expensive process to produce insulin and made it far better, cheaper, and faster.
That innovative changed the insulin production industry forever and InMed has the potential to do the same...only in marijuana.
InMed’s patented biosynthesis processes can do for GW Pharmaceuticals and the dozens of other cannabinoid-based pharmaceuticals in development that Genentech did for Eli Lilly.
Just like there won’t be endless trainload of pig organs shipped across the central United States, InMed’s biosynthesis process permits the cannabinoids to be developed without having to build, maintain, and fund acres of marijuana farms.
Not to mention, drastically reduce the costs of getting the cannabinoids in the first place.
There couldn’t be a better time to be doing it either.
A True Billionaire-Make Idea
Recent referenda in the United States has propelled marijuana into the mainstream.
There will be all sorts of opportunities in the sector as the marijuana industry grows in the years ahead.
However, InMed Pharmaceuticals (IMLFF) isn’t a regular marijuana stock that’s going to go through the ups and downs of the market, hit endless regulatory hurdles, and get involved in endless political fights.
InMed has targeted a clear and distinct opportunity historically proven to have multi-billion dollar potential.
Looking ahead at companies like GW Pharmaceuticals and many others will have tapped into the medicinal properties which have made marijuana a widely-used healing drug for centuries despite its narcotic properties.
InMed and its patented and proprietary process for creating the building blocks for all these biotech discoveries will go a long way to supplying the critical and costly cannabinoids essential to these pharmaceuticals’ capabilities.
There once was a time when millions of pig pancreases were shipped across the country to create insulin therapies at great expense.
One innovation ended all that and made early investors in Genentech, the company that discovered the process, into billionaires.
Today there are marijuana farms being built out just to supply the tiniest amounts of key cannabinoids to produce marijuana-based pharmaceuticals.
This process will change too thanks to innovations already made by InMed Pharmaceuticals.
Investors looking for a unique way to get on the rapidly unfolding medical marijuana boom with a stock that hasn’t run yet should take a look at InMed Pharmaceuticals (IMLFF) now.
https://investors.inmedpharma.com/
What is Biosynthesis?
U N L O C K I N G C A N N A B I N O I D M E D I C I N E S
Biosynthesis is a way to mimic what naturally happens in the plant: a
multi-step, enzyme-catalyzed process where components are converted
into more complex compounds inside living organisms
Performed using the same starting material as the plant – a gene;
simple compounds are modified, converted into other compounds, or
joined together to form macromolecules
Bacteria (E. coli) is genetically programmed to create the enzymes
needed to convert starting materials into more complex compounds
Investor Presentation • January 2019 • InMed Pharmaceuticals
Several Benefits of our Biosynthesis Technology
U N L O C K I N G C A N N A B I N O I D M E D I C I N E S
Significant cost and time savings vs. existing growing / harvesting / extraction /
purification methods
Increased structural integrity when compared to chemical manufacturing methods
Access to minor cannabinoids that are currently economically unfeasible via plant
extraction (and, possibly, chemical manufacturing)
Enhanced production, purification, and quality control when compared to naturallysourced products
Investor Presentation • January 2019 • InMed Pharmaceuticals
Significant Revenue Opportunities
U N L O C K I N G C A N N A B I N O I D M E D I C I N E S
Three distinct revenue opportunities from biosynthesis:
Supplier of drug product to the pharmaceutical industry:
• Global annual sales of Epidiolex® are expected to peak at ~$2.2B a
• Continued approvals in this space will grow this opportunity
2 Provider of raw materials (terpenes) to the flavors and fragrance market:
• The global aroma chemicals market is currently $4.1b, and expected to grow
to $6.5B by 2021b
3 Provider of pharmaceutical-grade ingredients to the legal cannabis market:
• WW sales of legal cannabis is currently $16.6b, which is expected to grow to
$35.8B by 2021 (CAGR=21%)
IMLFF has a chance to 100x once the Biosynthesis is up and running and generating revenue. IMLFF has a chance to be the go to for the industry for Pharma grade Bio synthesis Cannabinoids. Great Team in place to get the company to a Billion dollar Blockbuster. Ely Lilly market cap grew by the tens of billions after their bio synthesis for insulin was created Mr Ben Patterson was in charge of Eli Lilly Bio Synthesis program and is now assisting IMLFF setting up their Bio Synthesis program.